Patents by Inventor Kenneth Arrington

Kenneth Arrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Checkpoint Kinases
    Publication number: 20080004259
    Abstract: The instant invention provides for compounds which comprise substituted indolyl indazoles that inhibit CHK1 activity. The instant compounds provide a novel mechanism of action with unexpected advantageous properties; such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: February 3, 2006
    Publication date: January 3, 2008
    Inventors: Kenneth Arrington, Mark Fraley, Robert Garbaccio, Shaei Huang, Craig Lindsley, Justin Steen, Feng Yang
  • Mitotic kinesin inhibitors
    Publication number: 20070149553
    Abstract: The present invention relates to 2-phenylthienylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: December 15, 2004
    Publication date: June 28, 2007
    Inventors: Kenneth Arrington, Mark Fraley, George Hartman
  • Mitotic kinesin inhibitors
    Publication number: 20070129356
    Abstract: The present invention relates to 2-phenylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: December 15, 2004
    Publication date: June 7, 2007
    Inventors: Kenneth Arrington, Mark Fraley, George Hartman
  • Mitotic kinesin inhibitors
    Publication number: 20070060601
    Abstract: The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: December 15, 2004
    Publication date: March 15, 2007
    Inventors: Kenneth Arrington, Mark Fraley, George Hartman
  • Mitotic kinesin inhibitors
    Publication number: 20060105997
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 12, 2003
    Publication date: May 18, 2006
    Inventors: Kenneth Arrington, Paul Coleman, Christopher Cox, Mark Fraley, Robert Garbaccio, George Hartman, William Hoffman, Edward Tasber
  • Mitotic kinesin inhibitors
    Publication number: 20060063942
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 12, 2003
    Publication date: March 23, 2006
    Inventors: Kenneth Arrington, Mark Fraley
  • Tyrosine kinase inhibitors
    Publication number: 20050096344
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: July 28, 2004
    Publication date: May 5, 2005
    Inventors: Mark Fraley, Kenneth Arrington, Mark Bilodeau, George Hartman, William Hoffman, Yuntae Kim, Randall Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20050070546
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: September 10, 2002
    Publication date: March 31, 2005
    Inventors: Kenneth Arrington, Mark Fraley, Barbara Hanney, Yuntae Kim, Keith Spencer